If you have been reading about anti-doping analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-03. Numbers and descriptions here follow the published literature rather than marketing material.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
=== Early life and education === William H. Stein was born on June 25, 1911 in New York City into a Jewish family. His father, Fred M. Stein, was a businessman who retired early to support local New York health organizations. His mother, Beatrice Borg Stein, was a children's rights activist who developed afterschool activities. Staunch advocates for the welfare of society, Stein's parents fostered his interests in the life sciences from a young age. As a child, Stein attended the recently established "progressive" Lincoln School which was sponsored by the Teachers College of Columbia University; there, he was able to explore the natural sciences through field trips and science projects. At the age of sixteen, Stein was transferred to the Phillips Exeter Academy in New England to prepare for higher education. In 1936, during his graduate studies at Columbia University, William H. Stein married Phoebe Hockstader. They had three sons together: William H. Stein, Jr., David F. Stein, and Robert J. Stein. Stein lived with his family in New York the rest of his life—mainly in Manhattan and briefly in Scarsdale, New York.
==== In foals ==== Investigators from Brazil used foals in an attempt to quantify the pain of freeze branding compared to hot branding. Two groups of foals were fitted with heart monitors and randomly assigned either freeze branding or hot branding. Blood samples were taken 30 minutes before branding and then again, 30 and 60 minutes after branding. Hot brands were applied for 3 seconds or less and liquid nitrogen-chilled freeze brands were applied for 60 seconds (sic). The foals were video-recorded during their branding for later ethological analysis by two veterinarians. These experts in horse body language scrutinized the recordings and assigned scores based on how many indications of pain each foal exhibited during branding. The score ranged from 0 to 6 and attempted to quantify the distress, if any, shown by the foals. Cortisol levels were determined from the three blood samples and heart rates were recorded until 60 minutes after branding. No sham-branded control group was used. Their analysis of collected data indicated that "both hot and freeze iron branding induced stress responses in foals, with a similar increase in the cortisol levels and intense pain and escape behavioral response" but that freeze branding resulted in less autonomic (fight-or-flight) response, suggesting that hot branding was the more stressful of the two procedures. This, combined with the lesser severity of wounds created by the freeze brands led the experimenters to conclude that freeze branding was the better choice. The results led the authors to recommend the prohibition of hot branding.
Furthermore, 3D "organoid" models of female reproductive tissue, such as the uterus and ovaries, produced from iPSCs, present a way to stimulate the development of reproductive disorders such as PMOS in vitro.
== Units and unit conversions == The serum concentration of prolactin can be given in mass concentration (μg/L or ng/mL), molar concentration (nmol/L or pmol/L), or international units (typically mIU/L). The current IU is calibrated against the third International Standard for Prolactin, IS 84/500. Reference ampoules of IS 84/500 contain "approximately" 2.5 μg of lyophilized human prolactin and have been assigned an activity of 0.053 International Units by calibrating against the previous standard. Measurements can be converted into mass units using this ratio of grams to IUs to obtain an equivalent in relationship to the contents of IS 84/500; prolactin concentrations expressed in mIU/L can be converted to μg/L of IS 84/500 equivalent by dividing by 21.2. Previous standards had other ratios in relation to their potency on the assay measurement. For example, the previous IS (83/562) had a potency of 27.0 mIU per μg. The first International Reference Preparation (or IRP) of human Prolactin for Immunoassay was established in 1978 (75/504 1st IRP for human prolactin) at a time when purified human prolactin was in short supply. Previous standards relied on prolactin from animal sources. Purified human prolactin was scarce, heterogeneous, unstable, and difficult to characterize. A preparation labeled 81/541 was distributed by the WHO Expert Committee on Biological Standardization without official status and given the assigned value of 50 mIU/ampoule based on an earlier collaborative study.
== PEGylated drugs == The attachment of an inert and hydrophilic polymer was first reported around 1970 to extend blood life and control immunogenicity of proteins. Polyethylene glycol was chosen as the polymer. In 1981 Davis and Abuchowski founded Enzon, Inc., which brought three PEGylated drugs to market. Abuchowski later founded and is CEO of Prolong Pharmaceuticals. The clinical value of PEGylation is now well established. ADAGEN (pegademase bovine) manufactured by Enzon Pharmaceuticals, Inc., US was the first PEGylated protein approved by the U.S. Food and Drug Administration (FDA) in March 1990, to enter the market. It is used to treat a form of severe combined immunodeficiency syndrome (ADA-SCID), as an alternative to bone marrow transplantation and enzyme replacement by gene therapy. Since the introduction of ADAGEN, a large number of PEGylated protein and peptide pharmaceuticals have followed and many others are under clinical trial or under development stages. Sales of the two most successful products, Pegasys and Neulasta, exceeded $5 billion in 2011. All commercially available PEGylated pharmaceuticals contain methoxypoly(ethylene glycol) or mPEG. PEGylated pharmaceuticals on the market (in reverse chronology by FDA approval year) have included:
Sources: en.wikipedia.org
== Formal scientific review == In 2006, the U.S. National Academy of Sciences released the report of a study of molecular manufacturing (not molecular assemblers per se) as part of a longer report, A Matter of Size: Triennial Review of the National Nanotechnology Initiative The study committee reviewed the technical content of Nanosystems, and in its conclusion states that no current theoretical analysis can be considered definitive regarding several questions of potential system performance, and that optimal paths for implementing high-performance systems cannot be predicted with confidence. It recommends funding for experimental research to produce experimental demonstrations in this area: "Although theoretical calculations can be made today, the eventually attainable range of chemical reaction cycles, error rates, speed of operation, and thermodynamic efficiencies of such bottom-up manufacturing systems cannot be reliably predicted at this time. Thus, the eventually attainable perfection and complexity of manufactured products, while they can be calculated in theory, cannot be predicted with confidence. Finally, the optimum research paths that might lead to systems which greatly exceed the thermodynamic efficiencies and other capabilities of biological systems cannot be reliably predicted at this time. Research funding that is based on the ability of investigators to produce experimental demonstrations that link to abstract models and guide long-term vision is most appropriate to achieve this goal."
Reflecting on her time at school, Collins said "I remember sitting in the exam room for my maths GCSE and thinking, "I'm going to be famous, I don't need maths." Collins had various Saturday jobs as a teenager, including working in a sweet shop and at the clothes shop Warehouse, before becoming a waitress at a local pub called The Orange Tree. After leaving school, she subsequently signed up to a media studies course at South Essex College but stopped attending after a few weeks as she found it boring. Collins also held a job at the clothes shop Benetton and spent several weeks working in a care home, looking after those who were suffering from mental illnesses. Her first appearance on television was in the ITV documentary Snobs, which aired in January 2000. The series focused on people who believed they were a different class. Following her appearance on the show, Collins, aged 18 at the time, visited an agent who told her that she "had charisma but was too fat to be on TV" and suggested that she should lose two stone. Collins held various admin jobs and roles working on reception during her twenties, as well as being an assistant to a senior executive at stockbrokers Cantor Fitzgerald which Collins said she "blagged" by being confident in interviews. She subsequently worked at a recruitment agency in London before becoming a receptionist at a BMW showroom in Harold Wood, where she retrained to become a sales executive.
== Discussion == Cosmetic surgery providers often advise their patients that many options now exist for improving the appearance of the lips. Most practitioners also admit that successful lip augmentation is highly dependent on the skill of the provider, with that skill stemming from many years of experience injecting the lips of many types of patients. Moreover, the surgeon must master various injection techniques. With many injectables, the benefit to the patient is an immediate return to normal, usual activities. A few surgeons offer a procedure known as surgical flap augmentations, in which small sections of skin near the lips or inside the mouth are excised and added to the lips. This technique does not add volume and achieves only a slight outward protrusion of the lips.
Stoess, on the other hand, had reestablished relations with Eastman Kodak in the United States and was bringing large quantities of much-needed foreign exchange to Germany. After World War II, Paul Koepff Jr. became managing director of the Stoess company in Eberbach. In 1949, he built up a gelatin capsule factory there. In the course of the decades, DGF AG bought various factories worldwide. In 1965, it was taken over by the "Chem. Werke Stoess" in Heidelberg. In that year Heinrich Koepff took over the majority of shares of the Göppingen plant and through his marriage to the granddaughter of the company founder, Gerda Stoess, the companies merged. In 1972, the association traded under the name DGF Stoess & Co. GmbH. In 1989, the company was converted into a public limited company. The gelatin production division was renamed the Gelita Group in 1999. In 2005, all entities started to sell gelatine under the brand name Gelita.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.